Marker Therapeutics, Inc. (MRKR)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Marker Therapeutics, Inc. (MRKR)

Company Performance

Current Price

as of Oct 16, 2024

$3.52

P/E Ratio

N/A

Market Cap

$31.41M

Description

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Metrics

Overview

HQHouston, TX
SectorHealth Technology
IndustryBiotechnology
TickerMRKR
Price$3.52+7.65%

Trading Information

Market Cap$31.41M
Float72.27%
Average Daily Volume (1m)40,431
Average Daily Volume (3m)32,137
EPS-$1.16

Company

Revenue$3.73M
Rev Growth (1yr)53.31%
Net Income-$2.19M
Gross MarginN/A
EBITDA Margin-197.40%
EBITDA-$2.31M

EV$40.63M
EV/Revenue10.90
P/EN/A
P/S8.42
P/B3.23

Documents

Earnings Calls

Earnings Report 2021Q1

Earnings Report (2021-05-12)

Factset

Factset Business Description

Factset Street Account

Marker Therapeutics reports Q3 EPS ($0.34) vs year-ago ($0.83) ($2.98, 0.00) (2023-11-09T22:02:47Z)

Marker Therapeutics appoints President and CEO Juan Vera as Principal Financial and Accounting Officer. - 8-K ($2.70, 0.00) (2023-11-20T21:53:30Z)